Provenge Improves Survival in Men With Advanced Prostate Cancer

Dendreon has announced that Provenge, the company's investigational immunotherapy for the treatment of prostate cancer, significantly improved survival in men with asymptomatic, metastatic androgen-independent (hormone-refractory) prostate cancer when compared to patients receiving placebo.

According to the final three-year intent-to-treat analysis of the company's first randomized Phase III clinical study, known as Study D9901, patients receiving Provenge had a 4.5 month improvement in their median survival and a greater than three-fold increase in survival at 36 months when compared to patients receiving placebo.